(Q34147950)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Stefan Koehrer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sabine Strommer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Daniel Cejka

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Thorsten Fuereder

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Eva Zebedin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Volker Wacheck

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

4 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

Journal of Investigative Dermatology

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

495-503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/jid.2010.327

15 January 2020

exact match

0 references

cites work

Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

The selectivity of protein kinase inhibitors: a further update

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Characterization of the FKBP.rapamycin.FRB ternary complex

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

The Akt/PKB pathway: molecular target for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Oncogenic signaling of class I PI3K isoforms

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

The Akt-mTOR tango and its relevance to cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

mTOR is activated in the majority of malignant melanomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Oncogenic PI3K and its role in cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

SnapShot: mTOR signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Deregulated Akt3 activity promotes development of malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

PTEN signaling pathways in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.327

7 January 2021

Identifiers

DOI

10.1038/JID.2010.327

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21048785%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

15 January 2020

0 references

1 reference